Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARA SHELBY FRIEDMAN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1649318569
CMS profile
979795
Location
ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,024.97

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,418.97 6
Food and Beverage $606.00 10

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $3,024.97 16

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARA SHELBY FRIEDMAN

NPI 1649318569 · CMS profile ID 979795

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1649318569?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $3,024.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $240.0009/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560398 CMS
ModernaTX, Inc. $718.4609/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560400 CMS
ModernaTX, Inc. $531.0609/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560402 CMS
ModernaTX, Inc. $45.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560404 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560406 CMS
ModernaTX, Inc. $81.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560408 CMS
ModernaTX, Inc. $30.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560410 CMS
ModernaTX, Inc. $120.0009/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560416 CMS
ModernaTX, Inc. $520.8001/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560382 CMS
ModernaTX, Inc. $191.3001/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560384 CMS
ModernaTX, Inc. $150.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560386 CMS
ModernaTX, Inc. $217.3501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560388 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560390 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560392 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560394 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560396 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $169.09 11
PY2023 $1,724.29 6
PY2024 $3,024.97 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,296,266.41 159
PY2024 Principal investigator $1,078,411.75 127
PY2023 Principal investigator $776,040.20 596
PY2022 Principal investigator $318,257.95 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

159 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Currax Pharmaceuticals LLC $7,182.84 12/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718360
Principal investigator 1 ModernaTX, Inc. $10,000.00 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946802
Principal investigator 1 ModernaTX, Inc. $9,927.50 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976761
Principal investigator 1 ModernaTX, Inc. $835.05 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976909
Principal investigator 1 ModernaTX, Inc. $2,215.40 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976965
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976797
Principal investigator 1 ModernaTX, Inc. $750.00 12/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976803
Principal investigator 1 ModernaTX, Inc. $1,800.00 12/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976855
Principal investigator 1 ModernaTX, Inc. $750.00 12/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976875
Principal investigator 1 ModernaTX, Inc. $2,505.15 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976811
Principal investigator 1 ModernaTX, Inc. $992.75 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976813
Principal investigator 1 ModernaTX, Inc. $2,528.90 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976885
Principal investigator 1 SANOFI PASTEUR INC. $1,325.16 11/26/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226089916
Principal investigator 1 SANOFI PASTEUR INC. $200.00 11/26/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226089929
Principal investigator 1 ModernaTX, Inc. $30,000.00 11/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946800
Principal investigator 1 ModernaTX, Inc. $166.72 11/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976973
Principal investigator 1 Currax Pharmaceuticals LLC $6,206.56 11/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718236
Principal investigator 1 SANOFI PASTEUR INC. $14,500.00 11/03/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226090288
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 11/03/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226114696
Principal investigator 1 Currax Pharmaceuticals LLC $1,300.00 10/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718172
Principal investigator 1 ModernaTX, Inc. $835.05 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976777
Principal investigator 1 ModernaTX, Inc. $2,549.80 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976961
Principal investigator 1 Currax Pharmaceuticals LLC $630.50 10/23/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718190
Principal investigator 1 ModernaTX, Inc. $1,390.61 10/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976915
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976751
Principal investigator 1 ModernaTX, Inc. $3,000.00 10/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976943
Principal investigator 1 Currax Pharmaceuticals LLC $8,838.73 10/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718096
Principal investigator 1 ModernaTX, Inc. $325.00 10/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976809
Principal investigator 1 ModernaTX, Inc. $1,223.88 10/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976837
Principal investigator 1 ModernaTX, Inc. $3,061.85 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976775
Principal investigator 1 ModernaTX, Inc. $2,278.10 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976895
Principal investigator 1 ModernaTX, Inc. $350.00 09/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976865
Principal investigator 1 ModernaTX, Inc. $1,800.00 09/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976743
Principal investigator 1 ModernaTX, Inc. $800.00 09/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976935
Principal investigator 1 ModernaTX, Inc. $2,329.96 09/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252976785
Principal investigator 1 ModernaTX, Inc. $500.00 09/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976791
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976851
Principal investigator 1 ModernaTX, Inc. $1,113.40 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976759
Principal investigator 1 ModernaTX, Inc. $393.53 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976869
Principal investigator 1 ModernaTX, Inc. $2,654.30 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976883
Principal investigator 1 ModernaTX, Inc. $11,913.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976893
Principal investigator 1 ModernaTX, Inc. $200.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976899
Principal investigator 1 ModernaTX, Inc. $75.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976901
Principal investigator 1 ModernaTX, Inc. $686.85 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976953
Principal investigator 1 ModernaTX, Inc. $166.72 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976919
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 08/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192182842
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 08/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192182846
Principal investigator 1 PFIZER INC. $2,084.95 08/15/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING SUBSEQUENT PREGNANCIES AND PERSISTENCE OF IMMUNITY OF A SINGLE DOSE OF A BIVALENT RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE No dispute reported 06/30/2026 1228788521
Principal investigator 1 ModernaTX, Inc. $9,022.39 08/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252976779
Principal investigator 1 ModernaTX, Inc. $500.00 08/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976783
Principal investigator 1 ModernaTX, Inc. $150.00 08/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976923
Principal investigator 1 ModernaTX, Inc. $700.00 08/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976747
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976807
Principal investigator 1 ModernaTX, Inc. $381.68 08/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1252976737
Principal investigator 1 ModernaTX, Inc. $3,340.20 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976825
Principal investigator 1 ModernaTX, Inc. $564.30 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976887
Principal investigator 1 ModernaTX, Inc. $3,971.00 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976957
Principal investigator 1 ModernaTX, Inc. $700.00 07/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976871
Principal investigator 1 ModernaTX, Inc. $333.45 07/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976835
Principal investigator 1 AstraZeneca Pharmaceuticals LP $166,748.77 07/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) No dispute reported 06/30/2026 1185555842
Principal investigator 1 ModernaTX, Inc. $30,331.12 07/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252976913
Principal investigator 1 ModernaTX, Inc. $2,978.25 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976765
Principal investigator 1 ModernaTX, Inc. $1,630.20 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976891
Principal investigator 1 ModernaTX, Inc. $686.85 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976963
Principal investigator 1 Currax Pharmaceuticals LLC $7,182.84 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717956
Principal investigator 1 PFIZER INC. $18,042.00 06/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING SUBSEQUENT PREGNANCIES AND PERSISTENCE OF IMMUNITY OF A SINGLE DOSE OF A BIVALENT RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE No dispute reported 06/30/2026 1228777838
Principal investigator 1 ModernaTX, Inc. $5,845.35 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976763
Principal investigator 1 ModernaTX, Inc. $800.00 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252976829
Principal investigator 1 ModernaTX, Inc. $393.53 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976873
Principal investigator 1 ModernaTX, Inc. $686.85 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976897
Principal investigator 1 ModernaTX, Inc. $276.75 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252976911
Principal investigator 1 ModernaTX, Inc. $1,057.16 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976925
Principal investigator 1 ModernaTX, Inc. $2,257.20 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976955
Principal investigator 1 ModernaTX, Inc. $5,956.50 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976967
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252976969
Principal investigator 1 ModernaTX, Inc. $890.00 06/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976921
Principal investigator 1 ModernaTX, Inc. $75.00 06/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976931
Principal investigator 1 ModernaTX, Inc. $877.50 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976917
Principal investigator 1 ModernaTX, Inc. $350.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976877
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 06/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185555840
Principal investigator 1 Currax Pharmaceuticals LLC $2,600.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717627
Principal investigator 1 Currax Pharmaceuticals LLC $8,181.23 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717883
Principal investigator 1 Currax Pharmaceuticals LLC $2,978.30 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717916
Principal investigator 1 ModernaTX, Inc. $4,963.75 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976757
Principal investigator 1 ModernaTX, Inc. $2,424.40 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976821
Principal investigator 1 ModernaTX, Inc. $393.53 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976947
Principal investigator 1 ModernaTX, Inc. $6,123.70 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976959
Principal investigator 1 SANOFI PASTEUR INC. $4,500.00 05/27/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226090868
Principal investigator 1 Merck Sharp & Dohme LLC $15,500.00 05/26/2025 Non-covered Recipient Entity
Velocity Clinical Research, Albuquerque
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease No dispute reported 06/30/2026 1232932998
Principal investigator 1 ModernaTX, Inc. $854.28 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976741
Principal investigator 1 ModernaTX, Inc. $583.66 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976745
Principal investigator 1 ModernaTX, Inc. $138.37 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976793
Principal investigator 1 ModernaTX, Inc. $4,649.60 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976795
Principal investigator 1 ModernaTX, Inc. $4,388.86 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976799
Principal investigator 1 ModernaTX, Inc. $142.33 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976801
Principal investigator 1 ModernaTX, Inc. $1,806.35 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976833
Principal investigator 1 ModernaTX, Inc. $264.93 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976849
Principal investigator 1 ModernaTX, Inc. $3,195.48 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976857
Principal investigator 1 ModernaTX, Inc. $747.81 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976861
Principal investigator 1 ModernaTX, Inc. $160.28 05/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976933
Principal investigator 1 ModernaTX, Inc. $3,603.25 05/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252976789
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 05/14/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226091551
Principal investigator 1 GlaxoSmithKline, LLC. $127.89 05/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH ALBUQUERQUE
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192182837
Principal investigator 1 ModernaTX, Inc. $70.00 05/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976867
Principal investigator 1 ModernaTX, Inc. $162.50 05/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976839
Principal investigator 1 ModernaTX, Inc. $1,373.70 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976769
Principal investigator 1 ModernaTX, Inc. $8,072.15 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976827
Principal investigator 1 ModernaTX, Inc. $2,048.20 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976905
Principal investigator 1 Currax Pharmaceuticals LLC $4,466.17 04/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717763
Principal investigator 1 Currax Pharmaceuticals LLC $1,852.50 04/17/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717591
Principal investigator 1 ModernaTX, Inc. $2,456.67 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976975
Principal investigator 1 ModernaTX, Inc. $1,869.00 04/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252976739
Principal investigator 1 PFIZER INC. $1,279.80 04/07/2025 Non-covered Recipient Entity
Velocity Clinical Research Albuquerque
A PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING SUBSEQUENT PREGNANCIES AND PERSISTENCE OF IMMUNITY OF A SINGLE DOSE OF A BIVALENT RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE No dispute reported 06/30/2026 1228707405
Principal investigator 1 PFIZER INC. $72.15 04/07/2025 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING SUBSEQUENT PREGNANCIES AND PERSISTENCE OF IMMUNITY OF A SINGLE DOSE OF A BIVALENT RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE No dispute reported 06/30/2026 1228768326
Principal investigator 1 PFIZER INC. $131.75 04/07/2025 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING SUBSEQUENT PREGNANCIES AND PERSISTENCE OF IMMUNITY OF A SINGLE DOSE OF A BIVALENT RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE No dispute reported 06/30/2026 1228768689
Principal investigator 1 PFIZER INC. $61.55 04/07/2025 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF REVACCINATING PREGNANT PARTICIPANTS DURING SUBSEQUENT PREGNANCIES AND PERSISTENCE OF IMMUNITY OF A SINGLE DOSE OF A BIVALENT RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE No dispute reported 06/30/2026 1228770022
Principal investigator 1 ModernaTX, Inc. $1,328.10 04/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252976845
Principal investigator 1 AstraZeneca Pharmaceuticals LP $45,224.60 03/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185555838
Principal investigator 1 ModernaTX, Inc. $1,998.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976749
Principal investigator 1 ModernaTX, Inc. $1,373.70 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976771
Principal investigator 1 ModernaTX, Inc. $3,061.85 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976815
Principal investigator 1 ModernaTX, Inc. $11,913.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976889
Principal investigator 1 ModernaTX, Inc. $2,048.20 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976951
Principal investigator 1 ModernaTX, Inc. $2,242.63 03/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976927
Principal investigator 1 Currax Pharmaceuticals LLC $16,858.76 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717411
Principal investigator 1 PFIZER INC. $9,553.50 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228787461
Principal investigator 1 ModernaTX, Inc. $7,526.00 03/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252976831
Principal investigator 1 ModernaTX, Inc. $440.00 03/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1252976971
Principal investigator 1 ModernaTX, Inc. $1,985.50 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976755
Principal investigator 1 ModernaTX, Inc. $3,385.80 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976767
Principal investigator 1 ModernaTX, Inc. $7,793.80 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976773
Principal investigator 1 ModernaTX, Inc. $20,063.05 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976817
Principal investigator 1 ModernaTX, Inc. $2,875.64 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976859
Principal investigator 1 ModernaTX, Inc. $2,090.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976879
Principal investigator 1 ModernaTX, Inc. $4,219.09 02/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976929
Principal investigator 1 ModernaTX, Inc. $37,259.95 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976949
Principal investigator 1 ModernaTX, Inc. $2,400.00 02/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976843
Principal investigator 1 ModernaTX, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976853
Principal investigator 1 Currax Pharmaceuticals LLC $1,100.00 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717307
Principal investigator 1 Currax Pharmaceuticals LLC $1,748.52 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717329
Principal investigator 1 ModernaTX, Inc. $24,442.94 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976805
Principal investigator 1 ModernaTX, Inc. $5,732.30 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976753
Principal investigator 1 ModernaTX, Inc. $11,913.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976819
Principal investigator 1 ModernaTX, Inc. $1,170.40 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976823
Principal investigator 1 ModernaTX, Inc. $3,061.85 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976881
Principal investigator 1 ModernaTX, Inc. $1,358.50 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976903
Principal investigator 1 ModernaTX, Inc. $686.85 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976907
Principal investigator 1 ModernaTX, Inc. $1,204.06 01/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976781
Principal investigator 1 ModernaTX, Inc. $12,616.95 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age No dispute reported 06/30/2026 1252976787
Principal investigator 1 ModernaTX, Inc. $750.00 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus No dispute reported 06/30/2026 1252976945
Principal investigator 1 ModernaTX, Inc. $349.92 01/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976863
Principal investigator 1 ModernaTX, Inc. $1,512.00 01/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976939
Principal investigator 1 ModernaTX, Inc. $540.00 01/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976941
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $105,610.52 01/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH ALBUQUERQUE
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124560
Principal investigator 1 ModernaTX, Inc. $3,000.00 01/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976847
Principal investigator 1 ModernaTX, Inc. $400.00 01/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976937
Principal investigator 1 SANOFI PASTEUR INC. $200.00 01/16/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1226092250
Principal investigator 1 ModernaTX, Inc. $500.00 01/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252976841
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $411,417.14 01/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH ALBUQUERQUE
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124558